TG Therapeutics FY2025 EPS Forecast Raised by HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at HC Wainwright lifted their FY2025 earnings estimates for TG Therapeutics in a research report issued to clients and investors on Wednesday, January 15th. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will earn $1.26 per share for the year, up from their prior estimate of $1.17. HC Wainwright currently has a "Buy" rating and a $55.00 target price on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $0.07 per share.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. During the same quarter in the prior year, the business posted $0.73 EPS. TG Therapeutics's revenue was down 49.4% compared to the same quarter last year.

A number of other equities analysts also recently commented on TGTX. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, January 7th. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a "buy" rating and a $50.00 price target for the company. The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Finally, JPMorgan Chase & Co. raised their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, TG Therapeutics has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX traded down $0.94 during trading hours on Thursday, reaching $29.25. The stock had a trading volume of 1,022,190 shares, compared to its average volume of 3,054,842. TG Therapeutics has a twelve month low of $12.84 and a twelve month high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The business's fifty day moving average is $31.69 and its two-hundred day moving average is $25.63. The company has a market cap of $4.55 billion, a price-to-earnings ratio of -293.12 and a beta of 2.24.

Hedge Funds Weigh In On TG Therapeutics

Large investors have recently modified their holdings of the stock. NBC Securities Inc. raised its position in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 485 shares during the last quarter. Blue Trust Inc. increased its stake in shares of TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 849 shares during the period. ORG Wealth Partners LLC bought a new stake in shares of TG Therapeutics during the third quarter worth $53,000. Values First Advisors Inc. acquired a new position in shares of TG Therapeutics during the third quarter valued at $58,000. Finally, GAMMA Investing LLC boosted its holdings in TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after acquiring an additional 2,171 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares in the company, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares of the company's stock, valued at $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,358 shares of company stock valued at $781,497. Corporate insiders own 10.50% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.